Home / Stocks / Acutaas Chemicals Limited
ACUTAAS

Acutaas Chemicals Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹3,977.1

Change

-14.2 (-0.36%)

Open

₹3,991.3

Prev. Close

₹3,991.3

Day High

₹4,020.4

Day Low

₹3,940.5

Volume Analysis

Traded

287,902

Delivered

171,172

Delivery %

59.45%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (24.0%)
  • •Strong operating margin (39.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (56.1%)
  • •Strong 3-year revenue growth (29.5%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹4,098.06 ₹4,059.23 ₹4,018.16 ₹3,979.33 ₹3,938.26 ₹3,899.43 ₹3,858.36
Fibonacci ₹4,059.23 ₹4,028.71 ₹4,009.85 ₹3,979.33 ₹3,948.81 ₹3,929.95 ₹3,899.43
Camarilla ₹3,999.07 ₹3,991.75 ₹3,984.42 ₹3,979.33 ₹3,969.78 ₹3,962.45 ₹3,955.13

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+127.16%

1 Week

-0.48%

1 Month

+26.16%

3 Months

+25.5%

6 Months

+34.76%

1 Year

+129.57%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹471.41

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.84%

Net margin 27.56% × asset turnover 0.6x × equity multiplier 1.2x

Company Overview

Sector

Healthcare

Market Cap

₹32,281 Cr

P/E (TTM)

73.5

ROE

24.0%

Book Value

₹227.0

Face Value

₹5.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Acutaas Chemicals Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (24.0%); strong operating margin (39.0%); promoter holding is falling. Strong 3-year EPS growth (56.1%).

TopFund Score — Fundamentals Quality

74/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

0

Cash Flow

33

Corporate Governance

41

Momentum

93

Institutional Ownership

82

Business Quality

99

Risk & Volatility

80

Liquidity

84

From Screener.in

  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 45.8% CAGR over last 5 years
  • −Stock is trading at 17.4 times its book value
  • −Promoter holding has decreased over last 3 years: -6.27%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Acutaas Chemicals filed its Annual Sustainability Report for FY 2025-26.

Transcript for Earnings call for Q2 FY 2027 Financial Results held on October 27, 2026 is attached

Dr. Ashish Kumar Pandey appointed Assistant VP Operations from November 2, 2026; two SMPs reassigned.

Newspaper Publication of the Unaudited Financial Results for the second quarter ended September 30, 2026 as attached.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 172 166 225 177 247 275 308 207 306 393 433 330 437
Expenses + 148 140 182 147 198 206 224 156 211 243 249 217 261
Operating Profit 25 27 43 30 49 69 85 51 95 151 184 113 176
OPM % 14.0% 16.0% 19.0% 17.0% 20.0% 25.0% 28.0% 25.0% 31.0% 38.0% 42.0% 34.0% 40.0%
Other Income + -30 3 1 1 8 2 6 16 10 5 11 2 5
Interest 1 3 2 4 0 1 1 1 1 1 1 1 1
Depreciation 4 4 5 6 7 6 7 8 8 10 10 10 13
Profit before tax -10 24 37 20 50 63 83 58 96 145 184 104 167
Tax % 71.0% 25.0% 31.0% 26.0% 25.0% 28.0% 24.0% 24.0% 25.0% 27.0% 27.0% 28.0% 26.0%
Net Profit + -17 18 26 15 38 45 63 44 72 106 134 75 123
EPS in Rs -3 2 3 2 5 5 8 5 9 13 16 9 15
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 17 9 21 15 43 65 37 17 24 43 40 59 43

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 160 188 239 240 341 520 617 717 1,007 1,339 1,593
Expenses + 137 157 196 198 260 415 493 589 775 859 969
Operating Profit 23 31 42 42 80 105 123 128 232 480 623
OPM % 14.0% 16.0% 18.0% 17.0% 24.0% 20.0% 20.0% 18.0% 23.0% 36.0% 39.0%
Other Income + 0 3 0 2 1 3 4 -25 17 42 23
Interest 3 3 5 6 6 6 2 6 6 3 4
Depreciation 1 2 3 4 4 10 12 16 27 36 42
Profit before tax 19 28 35 35 72 91 112 82 216 483 600
Tax % 35.0% 35.0% 34.0% 21.0% 25.0% 21.0% 26.0% 41.0% 26.0% 26.0% —
Net Profit + 12 18 23 27 54 72 83 49 160 356 439
EPS in Rs 2 3 4 4 8 10 11 6 19 44 54
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 15.0% 13.0% 26.0% 8.0% 6.0% —
Sales growth — 17 27 0 42 53 19 16 40 33 45

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 37 56 72 101 135 486 558 637 1,269 1,613 1,817
Borrowings + 27 44 54 59 137 1 4 217 13 36 15
Other Liabilities + 43 54 77 61 110 136 169 205 227 295 348
Total Liabilities 109 155 213 232 413 659 767 1,096 1,549 1,984 2,221
Fixed Assets + 28 32 79 85 186 205 259 427 570 745 1,115
CWIP 11 30 2 12 0 3 30 125 130 332 67
Investments 1 3 2 2 1 2 2 0 0 0 0
Other Assets + 68 91 131 133 225 450 477 543 848 907 1,039
Total Assets 109 155 213 232 413 659 767 1,096 1,549 1,984 2,221
Equity Capital 2 2 10 10 32 36 36 37 41 41 41

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 29 8 15 27 28 -12 66 125 118 292
Cash from Investing Activity + -19 -25 -21 -24 -101 -121 -33 -365 -224 -266
Cash from Financing Activity + -7 15 6 0 72 140 -12 239 261 4
Net Cash Flow 3 -2 0 3 -1 8 20 -1 156 30
Free Cash Flow 10 -16 -7 6 -77 -46 -31 -155 -76 -36
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 153 53 68 85 52 10 73 116 71 84

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 39.91% → 32.66%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 40.85% 44.31% 36.28% 30.24% 28.27% 29.22% 28.0% 27.89% 28.96% 28.24% 26.16% 25.31%
Promoters 39.91% 39.91% 35.98% 35.97% 35.96% 35.96% 32.66% 32.66% 32.66% 32.66% 32.66% 32.66%
Government 0.0% 0.0% 0.0% 0.0% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
FII 11.66% 8.98% 12.93% 13.87% 15.52% 16.48% 16.94% 16.84% 16.67% 19.48% 21.61% 22.61%
DII 7.58% 6.8% 14.81% 19.93% 20.23% 18.31% 22.38% 22.59% 21.7% 19.6% 19.55% 19.4%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Acutaas Chemicals Limited (this stock) 32,281 73.5 17.37 24.0%
Piramal Pharma Limited 32,557 — 4.0 -3.83%
Krishna Inst Of Med Sci L 31,903 157.0 8.11 11.3%
Wockhardt Limited 32,944 82.4 6.39 6.11%
Dr. Lal Path Labs Ltd. 33,582 55.5 12.2 22.3%
Rubicon Research Limited 27,764 85.5 19.59 27.0%
Neuland Lab Ltd. 27,106 59.9 13.35 21.2%

Which Mutual Funds Hold Acutaas Chemicals Limited?

Frequently Asked Questions about Acutaas Chemicals Limited

Community Sentiment

What are other investors saying about Acutaas Chemicals Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.